Clinical Trials Browser

Phase 2 × INDUSTRY × dostarlimab × Clear all

NCT05723562 2026-05-26

AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT06062420 2026-05-22

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06567782 2026-05-22

AZUR-4

Phase 2 Recruiting

Gastrointestinal

Colonic Neoplasms

NCT05565378 2026-01-08

A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT07108270 2025-12-22

A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)

Phase 2 Recruiting

Endometrial Neoplasms

NCT06640049 2025-11-17

China AZUR-1

Phase 2 Active not recruiting

Gastrointestinal

Rectal Neoplasms

NCT04581824 2025-08-08

Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

Phase 2 Terminated

243 enrolled 21 charts

Carcinoma, Non-Small-Cell Lung

NCT06317311 2025-07-25

RUBY-J

Phase 2 Active not recruiting

Carcinoma, Endometrial Neoplasms

NCT03574779 2025-07-15

OPAL

Phase 2 Completed

77 enrolled 8 charts

Ovarian Neoplasms

NCT06926673 2025-07-03

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 3

Phase 2 Completed

62 enrolled 36 charts

Neoplasms

NCT03739710 2025-06-15

Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Phase 2 Completed

175 enrolled 5 charts

Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT05126342 2025-04-06

Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi

Phase 2 Withdrawn

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03308942 2023-10-16

Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants

Phase 2 Completed

53 enrolled 35 charts

Neoplasms

NCT05751629 2023-04-21

COHORT-A

Phase 2 Completed

41 enrolled 17 charts

Ovarian Neoplasms

NCT03955471 2022-09-10

MOONSTONE

Phase 2 Terminated

41 enrolled 22 charts

Ovarian Neoplasms